ACE and COVID-19: Recently, Sama et al. (2020) reported that neither ACE inhibitors, ARBs, nor mineralocorticoid receptor antagonists were associated with ACE2 concentrations in plasma in a wide cohort of patients with heart failure, albeit a group at high risk for COVID-19 (48).